{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T10:00:33Z","timestamp":1784368833565,"version":"3.55.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T00:00:00Z","timestamp":1699660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T00:00:00Z","timestamp":1699660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s00417-023-06313-9","type":"journal-article","created":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T07:02:03Z","timestamp":1699686123000},"page":"1305-1320","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Central subfield thickness predicts visual acuity outcomes in plaque-irradiated eyes with choroidal melanoma"],"prefix":"10.1007","volume":"262","author":[{"given":"Saumya M.","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurel B.","family":"Tanke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher L.","family":"Deufel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivy A.","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly S.","family":"Corbin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David O.","family":"Hodge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy W.","family":"Olsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9710-4284","authenticated-orcid":false,"given":"Lauren A.","family":"Dalvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,11]]},"reference":[{"key":"6313_CR1","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1097\/01.icu.0000193079.55240.18","volume":"17","author":"CL Shields","year":"2006","unstructured":"Shields CL, Shields JA (2006) Basic understanding of current classification and management of retinoblastoma. Curr Opin Ophthalmol 17:228\u2013234. https:\/\/doi.org\/10.1097\/01.icu.0000193079.55240.18","journal-title":"Curr Opin Ophthalmol"},{"key":"6313_CR2","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/EYE.2016.275","volume":"31","author":"S Kaliki","year":"2017","unstructured":"Kaliki S, Shields CL (2017) Uveal melanoma: relatively rare but deadly cancer. Eye 31:241. https:\/\/doi.org\/10.1038\/EYE.2016.275","journal-title":"Eye"},{"key":"6313_CR3","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/S0161-6420(02)01277-0","volume":"109","author":"L Jampol","year":"2002","unstructured":"Jampol L, Moy C, Murray T et al (2002) The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: IV. Local treatment failure and enucleation in the first 5 years after brachytherapy. COMS report no. 19. Ophthalmology 109:2197\u20132206. https:\/\/doi.org\/10.1016\/S0161-6420(02)01277-0","journal-title":"Ophthalmology"},{"key":"6313_CR4","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1001\/JAMAOPHTHALMOL.2019.5132","volume":"138","author":"CL Shields","year":"2020","unstructured":"Shields CL, Dalvin LA, Chang M et al (2020) Visual outcome at 4 years following plaque radiotherapy and prophylactic intravitreal bevacizumab (every 4 months for 2 years) for uveal melanoma: comparison with nonrandomized historical control individuals. JAMA Ophthalmol 138:136\u2013146. https:\/\/doi.org\/10.1001\/JAMAOPHTHALMOL.2019.5132","journal-title":"JAMA Ophthalmol"},{"key":"6313_CR5","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1136\/BJOPHTHALMOL-2019-314686","volume":"104","author":"L Dalvin","year":"2020","unstructured":"Dalvin L, Zhang Q, Hamershock R et al (2020) Nomogram for visual acuity outcome after iodine-125 plaque radiotherapy and prophylactic intravitreal bevacizumab for uveal melanoma in 1131 patients. Br J Ophthalmol 104:697\u2013702. https:\/\/doi.org\/10.1136\/BJOPHTHALMOL-2019-314686","journal-title":"Br J Ophthalmol"},{"key":"6313_CR6","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1097\/IAE.0B013E31814B1B75","volume":"28","author":"N Horgan","year":"2008","unstructured":"Horgan N, Shields CL, Mashayekhi A et al (2008) Early macular morphological changes following plaque radiotherapy for uveal melanoma. Retina 28:263\u2013273. https:\/\/doi.org\/10.1097\/IAE.0B013E31814B1B75","journal-title":"Retina"},{"issue":"6","key":"6313_CR7","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1038\/eye.2009.43","volume":"23","author":"JC Wen","year":"2009","unstructured":"Wen JC, Oliver SC, McCannel TA (2009) Ocular complications following I-125 brachytherapy for choroidal melanoma. Eye 23(6):1254\u20131268. https:\/\/doi.org\/10.1038\/eye.2009.43","journal-title":"Eye"},{"key":"6313_CR8","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1097\/IAE.0B013E3182437E70","volume":"32","author":"MA Materin","year":"2012","unstructured":"Materin MA, Bianciotto CG, Wu C, Shields CL (2012) Sector laser photocoagulation for the prevention of macular edema after plaque radiotherapy for uveal melanoma: a pilot study. Retina 32:1601\u20131607. https:\/\/doi.org\/10.1097\/IAE.0B013E3182437E70","journal-title":"Retina"},{"key":"6313_CR9","doi-asserted-by":"publisher","first-page":"34","DOI":"10.17925\/USOR.2020.13.1.34","volume":"13","author":"HJ Yu","year":"2020","unstructured":"Yu HJ, Schefler AC (2020) Radiation retinopathy\u2014a review of past and current treatment strategies. US Ophthalmic Rev 13:34. https:\/\/doi.org\/10.17925\/USOR.2020.13.1.34","journal-title":"US Ophthalmic Rev"},{"key":"6313_CR10","doi-asserted-by":"publisher","first-page":"158","DOI":"10.3129\/I10-111","volume":"46","author":"H Krema","year":"2011","unstructured":"Krema H, Xu W, Payne D et al (2011) Factors predictive of radiation retinopathy post 125Iodine brachytherapy for uveal melanoma. Can J Ophthalmol 46:158\u2013163. https:\/\/doi.org\/10.3129\/I10-111","journal-title":"Can J Ophthalmol"},{"key":"6313_CR11","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1136\/BJO.84.9.1068","volume":"84","author":"PT Finger","year":"2000","unstructured":"Finger PT (2000) Tumour location affects the incidence of cataract and retinopathy after ophthalmic plaque radiation therapy. Br J Ophthalmol 84:1068\u20131070. https:\/\/doi.org\/10.1136\/BJO.84.9.1068","journal-title":"Br J Ophthalmol"},{"key":"6313_CR12","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.1167\/IOVS.04-0066","volume":"45","author":"I Puusaari","year":"2004","unstructured":"Puusaari I, Heikkonen J, Kivel\u00e4 T (2004) Effect of radiation dose on ocular complications after iodine brachytherapy for large uveal melanoma: empirical data and simulation of collimating plaques. Invest Ophthalmol Vis Sci 45:3425\u20133434. https:\/\/doi.org\/10.1167\/IOVS.04-0066","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"6313_CR13","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1097\/IAE.0B013E31816B3192","volume":"28","author":"N Horgan","year":"2008","unstructured":"Horgan N, Shields C, Mashayekhi A et al (2008) Periocular triamcinolone for prevention of macular edema after iodine 125 plaque radiotherapy of uveal melanoma. Retina 28:987\u2013995. https:\/\/doi.org\/10.1097\/IAE.0B013E31816B3192","journal-title":"Retina"},{"key":"6313_CR14","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/ICU.0000000000000141","volume":"26","author":"D Reichstein","year":"2015","unstructured":"Reichstein D (2015) Current treatments and preventive strategies for radiation retinopathy. Curr Opin Ophthalmol 26:157\u2013166. https:\/\/doi.org\/10.1097\/ICU.0000000000000141","journal-title":"Curr Opin Ophthalmol"},{"key":"6313_CR15","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/J.OPHTHA.2013.08.039","volume":"121","author":"SU Shah","year":"2014","unstructured":"Shah SU, Shields CL, Bianciotto CG et al (2014) Intravitreal bevacizumab at 4-month intervals for prevention of macular edema after plaque radiotherapy of uveal melanoma. Ophthalmology 121:269\u2013275. https:\/\/doi.org\/10.1016\/J.OPHTHA.2013.08.039","journal-title":"Ophthalmology"},{"key":"6313_CR16","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.ophtha.2014.12.034","volume":"122","author":"A Mashayekhi","year":"2015","unstructured":"Mashayekhi A, Sch\u00f6nbach E, Shields CL, Shields JA (2015) Early subclinical macular edema in eyes with uveal melanoma: association with future cystoid macular edema. Ophthalmology 122:1023\u20131029. https:\/\/doi.org\/10.1016\/j.ophtha.2014.12.034","journal-title":"Ophthalmology"},{"key":"6313_CR17","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1118\/1.3523614","volume":"38","author":"MJ Rivard","year":"2011","unstructured":"Rivard MJ, Chiu-Tsao ST, Finger PT et al (2011) Comparison of dose calculation methods for brachytherapy of intraocular tumors. Med Phys 38:306\u2013316. https:\/\/doi.org\/10.1118\/1.3523614","journal-title":"Med Phys"},{"key":"6313_CR18","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/J.BRACHY.2020.09.007","volume":"20","author":"CL Deufel","year":"2021","unstructured":"Deufel CL, McCauley Cutsinger S, Corbin KS et al (2021) EyeDose: an open-source tool for using published Monte Carlo results to estimate the radiation dose delivered to the tumor and critical ocular structures for 125 I Collaborative Ocular Melanoma Study eye plaques. Brachytherapy 20:189\u2013199. https:\/\/doi.org\/10.1016\/J.BRACHY.2020.09.007","journal-title":"Brachytherapy"},{"key":"6313_CR19","doi-asserted-by":"publisher","first-page":"381","DOI":"10.21873\/INVIVO.11784","volume":"34","author":"MM Pagliara","year":"2020","unstructured":"Pagliara MM, Tagliaferri L, Lenkowicz J et al (2020) AVATAR: analysis for visual acuity prediction after eye interventional radiotherapy. In Vivo (Brooklyn) 34:381. https:\/\/doi.org\/10.21873\/INVIVO.11784","journal-title":"In Vivo (Brooklyn)"},{"key":"6313_CR20","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/J.IJROBP.2005.02.059","volume":"63","author":"B Damato","year":"2005","unstructured":"Damato B, Patel I, Campbell IR et al (2005) Visual acuity after Ruthenium(106) brachytherapy of choroidal melanomas. Int J Radiat Oncol Biol Phys 63:392\u2013400. https:\/\/doi.org\/10.1016\/J.IJROBP.2005.02.059","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"6313_CR21","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.3390\/CANCERS11081124","volume":"11","author":"CA Espensen","year":"2019","unstructured":"Espensen CA, Appelt AL, Fog LS et al (2019) Predicting visual acuity deterioration and radiation-induced toxicities after brachytherapy for choroidal melanomas. Cancers (Basel) 11:1124. https:\/\/doi.org\/10.3390\/CANCERS11081124","journal-title":"Cancers (Basel)"},{"key":"6313_CR22","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1001\/ARCHOPHT.118.9.1219","volume":"118","author":"CL Shields","year":"2000","unstructured":"Shields CL, Shields JA, Cater J et al (2000) Plaque radiotherapy for uveal melanoma: long-term visual outcome in 1106 consecutive patients. Arch Ophthalmol 118:1219\u20131228. https:\/\/doi.org\/10.1001\/ARCHOPHT.118.9.1219","journal-title":"Arch Ophthalmol"},{"key":"6313_CR23","doi-asserted-by":"publisher","first-page":"3851","DOI":"10.1167\/IOVS.17-22324","volume":"58","author":"A Matet","year":"2017","unstructured":"Matet A, Daruich A, Zografos L (2017) Radiation maculopathy after proton beam therapy for uveal melanoma: optical coherence tomography angiography alterations influencing visual acuity. Invest Ophthalmol Vis Sci 58:3851\u20133861. https:\/\/doi.org\/10.1167\/IOVS.17-22324","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"6313_CR24","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3892\/MCO.2014.247","volume":"2","author":"M Yang","year":"2014","unstructured":"Yang M, Kuang X, Pan Y et al (2014) Clinicopathological characteristics of vascular endothelial growth factor expression in uveal melanoma: a meta-analysis. Mol Clin Oncol 2:363\u2013368. https:\/\/doi.org\/10.3892\/MCO.2014.247","journal-title":"Mol Clin Oncol"},{"key":"6313_CR25","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1001\/ARCHOPHT.124.10.1428","volume":"124","author":"GSO Missotten","year":"2006","unstructured":"Missotten GSO, Notting IC, Schlingemann RO et al (2006) Vascular endothelial growth factor A in eyes with uveal melanoma. Arch Ophthalmol 124:1428\u20131434. https:\/\/doi.org\/10.1001\/ARCHOPHT.124.10.1428","journal-title":"Arch Ophthalmol"},{"key":"6313_CR26","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1136\/BJO.86.4.448","volume":"86","author":"SR Boyd","year":"2002","unstructured":"Boyd SR, Tan D, Bunce C et al (2002) Vascular endothelial growth factor is elevated in ocular fluids of eyes harbouring uveal melanoma: identification of a potential therapeutic window. Br J Ophthalmol 86:448\u2013452. https:\/\/doi.org\/10.1136\/BJO.86.4.448","journal-title":"Br J Ophthalmol"},{"key":"6313_CR27","first-page":"648","volume":"61","author":"R Parrozzani","year":"2020","unstructured":"Parrozzani R, Frizziero L, Bini S et al (2020) Intraocular biomarkers in uveal melanoma: a proteomic study. Invest Ophthalmol Vis Sci 61:648\u2013652","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"6313_CR28","doi-asserted-by":"publisher","first-page":"599","DOI":"10.18240\/IJO.2020.04.11","volume":"13","author":"MX Chen","year":"2020","unstructured":"Chen MX, Liu YM, Yang L et al (2020) Elevated VEGF-A & PLGF concentration in aqueous humor of patients with uveal melanoma following Iodine-125 plaque radiotherapy. Int J Ophthalmol 13:599. https:\/\/doi.org\/10.18240\/IJO.2020.04.11","journal-title":"Int J Ophthalmol"},{"key":"6313_CR29","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1016\/S0161-6420(99)90455-4","volume":"106","author":"ES Gragoudas","year":"1999","unstructured":"Gragoudas ES, Li W, Lane AM et al (1999) Risk factors for radiation maculopathy and papillopathy after intraocular irradiation. Ophthalmology 106:1571\u20131578. https:\/\/doi.org\/10.1016\/S0161-6420(99)90455-4","journal-title":"Ophthalmology"},{"key":"6313_CR30","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/S0002-9394(98)00445-0","volume":"127","author":"K G\u00fcnd\u00fcz","year":"1999","unstructured":"G\u00fcnd\u00fcz K, Shields CL, Shields JA et al (1999) Radiation complications and tumor control after plaque radiotherapy of choroidal melanoma with macular involvement. Am J Ophthalmol 127:579\u2013589. https:\/\/doi.org\/10.1016\/S0002-9394(98)00445-0","journal-title":"Am J Ophthalmol"},{"key":"6313_CR31","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/J.SURVOPHTHAL.2020.08.007","volume":"66","author":"M Fallico","year":"2021","unstructured":"Fallico M, Chronopoulos A, Schutz JS, Reibaldi M (2021) Treatment of radiation maculopathy and radiation-induced macular edema: a systematic review. Surv Ophthalmol 66:441\u2013460. https:\/\/doi.org\/10.1016\/J.SURVOPHTHAL.2020.08.007","journal-title":"Surv Ophthalmol"},{"key":"6313_CR32","doi-asserted-by":"publisher","unstructured":"Myers CE, Klein BEK, Meuer SM et al (2014) Retinal thickness measured by spectral domain optical coherence tomography in eyes without retinal abnormalities: the Beaver Dam Eye Study. https:\/\/doi.org\/10.1016\/j.ajo.2014.11.025","DOI":"10.1016\/j.ajo.2014.11.025"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-023-06313-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-023-06313-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-023-06313-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T08:06:43Z","timestamp":1712218003000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-023-06313-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,11]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["6313"],"URL":"https:\/\/doi.org\/10.1007\/s00417-023-06313-9","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,11]]},"assertion":[{"value":"12 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Mayo Clinic Institutional Review Board deemed this study exempt as a retrospective chart review, and informed consent was obtained from all patients for inclusion in the IRB-approved Prospective Ocular Tumors Study (POTS) database.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The other authors have no relevant financial disclosures. Dr. Olsen is a board member of the American Academy of Ophthalmology, holds an unrelated grant NIH\/NEI R41EY028803 Novartis, and holds unrelated patents #08083751, #1986581, #9539082, #10278808.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Lauren A. Dalvin, M.D. has had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}